↓ Skip to main content

Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial

Overview of attention for article published in Trials, April 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (61st percentile)

Mentioned by

twitter
4 tweeters
facebook
2 Facebook pages

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
62 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Aspirin in venous leg ulcer study (ASPiVLU): study protocol for a randomised controlled trial
Published in
Trials, April 2016
DOI 10.1186/s13063-016-1314-4
Pubmed ID
Authors

Carolina D. Weller, Anna Barker, Ian Darby, Terrence Haines, Martin Underwood, Stephanie Ward, Pat Aldons, Elizabeth Dapiran, Jason J. Madan, Paula Loveland, Sankar Sinha, Mauro Vicaretti, Rory Wolfe, Michael Woodward, John McNeil

Abstract

Venous leg ulceration is a common and costly problem that is expected to worsen as the population ages. Current treatment is compression therapy; however, up to 50 % of ulcers remain unhealed after 2 years, and ulcer recurrence is common. New treatments are needed to address those wounds that are more challenging to heal. Targeting the inflammatory processes present in venous ulcers is a possible strategy. Limited evidence suggests that a daily dose of aspirin may be an effective adjunct to aid ulcer healing and reduce recurrence. The Aspirin in Venous Leg Ulcer study (ASPiVLU) will investigate whether 300-mg oral doses of aspirin improve time to healing. This randomised, double-blinded, multicentre, placebo-controlled, clinical trial will recruit participants with venous leg ulcers from community settings and hospital outpatient wound clinics across Australia. Two hundred sixty-eight participants with venous leg ulcers will be randomised to receive either aspirin or placebo, in addition to compression therapy, for 24 weeks. The primary outcome is time to healing within 12 weeks. Secondary outcomes are ulcer recurrence, wound pain, quality of life and wellbeing, adherence to study medication, adherence to compression therapy, serum inflammatory markers, hospitalisations, and adverse events at 24 weeks. The ASPiVLU trial will investigate the efficacy and safety of aspirin as an adjunct to compression therapy to treat venous leg ulcers. Study completion is anticipated to occur in December 2018. Australian New Zealand Clinical Trials Registry, ACTRN12614000293662.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 62 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Unknown 61 98%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 27%
Student > Bachelor 10 16%
Researcher 8 13%
Librarian 5 8%
Student > Doctoral Student 5 8%
Other 12 19%
Unknown 5 8%
Readers by discipline Count As %
Medicine and Dentistry 24 39%
Nursing and Health Professions 15 24%
Pharmacology, Toxicology and Pharmaceutical Science 4 6%
Biochemistry, Genetics and Molecular Biology 3 5%
Economics, Econometrics and Finance 3 5%
Other 4 6%
Unknown 9 15%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 March 2018.
All research outputs
#6,597,181
of 12,712,180 outputs
Outputs from Trials
#1,638
of 3,148 outputs
Outputs of similar age
#98,202
of 261,607 outputs
Outputs of similar age from Trials
#1
of 1 outputs
Altmetric has tracked 12,712,180 research outputs across all sources so far. This one is in the 47th percentile – i.e., 47% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,148 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 261,607 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them